Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario, Canada.
Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario, Canada.
Value Health. 2023 Jul;26(7):1107-1129. doi: 10.1016/j.jval.2023.02.010. Epub 2023 Feb 24.
In Canada, public insurance for physician and hospital services, without cost-sharing, is provided to all residents. Outpatient prescription drug coverage, however, is provided through a patchwork system of public and private plans, often with substantial cost-sharing, which leaves many underinsured or uninsured.
We conducted a systematic review to examine the association of drug insurance and cost-sharing with drug use, health services use, and health in Canada. We searched 4 electronic databases, 2 grey literature databases, 5 specialty journals, and 2 working paper repositories. At least 2 reviewers independently screened articles for inclusion, extracted characteristics, and assessed risk of bias.
The expansion of drug insurance was associated with increases in drug use, individuals who reported drug insurance generally reported higher drug use, and increases in and higher levels of drug cost-sharing were associated with lower drug use. Although a number of studies found statistically significant associations between drug insurance or cost-sharing and health services use, the magnitudes of these associations were generally fairly small. Among 5 studies that examined the association of drug insurance and cost-sharing with health outcomes, 1 found a statistically significant and clinically meaningful association. We did not find that socioeconomic status or sex were effect modifiers; there was some evidence that health modified the association between drug insurance and cost-sharing and drug use.
Increased cost-sharing is likely to reduce drug use. Universal pharmacare without cost-sharing may reduce inequities because it would likely increase drug use among lower-income populations relative to higher-income populations.
在加拿大,向所有居民提供不收取费用分担的公共医疗保险,用于支付医生和医院服务费用。然而,门诊处方药覆盖范围则通过公共和私人计划的拼凑系统来提供,通常伴随着大量的费用分担,这使得许多人保险不足或没有保险。
我们进行了一项系统综述,以考察加拿大的药物保险和费用分担与药物使用、卫生服务使用和健康之间的关联。我们检索了 4 个电子数据库、2 个灰色文献数据库、5 种专业期刊和 2 个工作论文存储库。至少有 2 名审查员独立筛选纳入的文章,提取特征,并评估偏倚风险。
药物保险的扩大与药物使用的增加有关,报告有药物保险的个人通常报告药物使用量较高,而药物保险和费用分担的增加和提高与较低的药物使用量有关。尽管许多研究发现药物保险或费用分担与卫生服务使用之间存在统计学上显著的关联,但这些关联的幅度通常相当小。在 5 项研究中,有 1 项研究发现药物保险和费用分担与健康结果之间存在统计学意义上且具有临床意义的关联。我们没有发现社会经济地位或性别是效应修饰剂;有一些证据表明健康状况改变了药物保险和费用分担与药物使用之间的关联。
增加费用分担可能会降低药物使用量。没有费用分担的全民药物保险可能会减少不平等现象,因为它可能会增加低收入人群相对于高收入人群的药物使用量。